If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-26. Numbers and descriptions here follow the published literature rather than marketing material.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Breath testing is a widespread method for quickly determining alcohol intoxication. A breath test measures the alcohol concentration in the body by a deep-lung breath. There are different instruments used for measuring the alcohol content of an individual though their breath. A Breathalyzer is a widely known instrument which was developed in 1954 and contained chemicals unlike other breath-testing instruments. More modern instruments include infrared light-absorption devices and fuel cell detectors. To get accurate readings on a breath-testing device the individual must blow for approximately 6 seconds and need to contain roughly 1.1 to 1.5 liters of breath. For a breath test to provide an accurate result an operator must take steps such as avoiding measuring "mouth alcohol" which is a result from regurgitation, belching, or recent intake of an alcoholic beverage. To avoid measuring "mouth alcohol" the operator must not allow the individual being tested to consume any materials for at least fifteen minutes before the breath test. In the United States, a driver who refuses to take a breath test can have their driver's license suspended for a period of 6 to 12 months.
PC Zone gave a rating of three out of five. Opposing Force CTF – A capture the flag mod based on Gearbox Software's expansion pack Half-Life: Opposing Force that was originally released in Half-Life patch 1.1.0.0. A standalone version was released a few months later. Oz Deathmatch – An early serverside mod that is a collection of deathmatch configuration options. Options that can be changed include magazine size, amount of blood, and weapon recoil. The mod also adds a new gadget, a grappling hook. The mod also supports Team Fortress Classic maps. In January 2000, it was listed among the top five HL mods on GameSpy's server browser. CNET Gamecenter placed it on its list of top 10 Half-Life mods, writing: "Oz has long been one of our favorite ways to deathmatch." Ricochet – An official Half-Life mod by Valve. It was released on November 1, 2000, and included in Half-Life's version 1.1.1.0 update, released on June 12, 2002. Ports of the game to OS X and Linux were released through Steam on August 1, 2013. Rocket Crowbar – An early mod that modifies every weapon in the game. For example the crowbar shoots "drunk" rockets and RPG shoots scientist and Barney modelled proximity mines. The mod also includes a capture the flag mode. Rocket Crowbar Redux: Source, was released for the Source engine. It includes weapons like gravity grenade and a scientist shotgun. Runaway Train – Similar to the game king of the hill, one player is on a train, the other players try to knock them off of it. The longer the player stays on the train, the more points they score.
The spleen is the largest lymphoid organ in the body but has other functions. It breaks down both red and white blood cells that are spent. This is why it is sometimes known as the 'graveyard of red blood cells'. A product of this digestion is the pigment bilirubin, which is sent to the liver and secreted in the bile. Another product is iron, which is used in the formation of new blood cells in the bone marrow. Medicine treats the spleen solely as belonging to the lymphatic system, though it is acknowledged that the full range of its important functions is not yet understood.
They were moved to the Château de Facqueval in Modave, Belgium, where Hahn used the time to work on his memoirs and then, on 3 July, were flown to England. They arrived at Farm Hall, Godmanchester, near Cambridge, on 3 July. While they were there, all their conversations, indoors and out, were covertly recorded with hidden microphones. They were given British newspapers, which Hahn was able to read. He was greatly disturbed by their reports of the Potsdam Conference, where German territory was ceded to Poland and the USSR. In August 1945, the German scientists were informed of the atomic bombing of Hiroshima. Up to this point the scientists, except Harteck, were completely certain that their project was further advanced than any in other countries, and the Alsos Mission's chief scientist, Samuel Goudsmit, did nothing to correct this impression. Now the reason for their incarceration in Farm Hall suddenly became apparent. As they recovered from the shock of the announcement, they began to rationalise what had happened. Hahn noted that he was glad that they had not succeeded, and von Weizsäcker suggested that they should claim that they had not wanted to. They drafted a memorandum on the project, noting that fission was discovered by Hahn and Strassmann. The revelation that Nagasaki had been destroyed by a plutonium bomb came as another shock, as it meant that the Allies had not only been able to conduct uranium enrichment, but had mastered nuclear reactor technology as well. The memorandum became the first draft of a postwar apologia.
Hyaluronic acid (; HA; conjugate base hyaluronate), also called hyaluronan, is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues. It is unique among glycosaminoglycans as it is non-sulfated, forms in the plasma membrane instead of the Golgi apparatus, and can be very large: human synovial HA averages about 7 MDa per molecule, or about 20,000 disaccharide monomers, while other sources mention 3–4 MDa. Medically, hyaluronic acid is used to treat osteoarthritis of the knee and dry eye, for wound repair, and as a cosmetic filler. These therapeutic uses are possible with modifications to HA, and more are still being developed. The average 70 kg (150 lb) person has roughly 15 grams of hyaluronan in the body, one third of which is turned over (i.e., degraded and synthesized) per day. As one of the chief components of the extracellular matrix, it contributes significantly to cell proliferation and migration, and is involved in the progression of many malignant tumors. Hyaluronic acid is also a component of the group A streptococcal extracellular capsule, and is believed to play a role in virulence. Chemical modifications to HA can improve certain properties such as biocompatibility, permeation, and sustained drug release. Common modification sites include the carboxyl, primary alcohol, and N-acetyl groups. These modifications include amidation, Ugi condensation, esterification, and etherification.
Sources: en.wikipedia.org
The alactic anaerobic system, which consists of high energy phosphates, adenosine triphosphate, and creatine phosphate; and The lactic anaerobic system, which features anaerobic glycolysis. High energy phosphates are stored in limited quantities within muscle cells. Anaerobic glycolysis exclusively uses glucose (and glycogen) as a fuel in the absence of oxygen, or more specifically, when ATP is needed at rates that exceed those provided by aerobic metabolism. The consequence of such rapid glucose breakdown is the formation of lactic acid (or more appropriately, its conjugate base lactate at biological pH levels). Physical activities that last up to about thirty seconds rely primarily on the former ATP-CP phosphagen system. Beyond this time, both aerobic and anaerobic glycolysis-based metabolic systems are used. The by-product of anaerobic glycolysis—lactate—has traditionally been thought to be detrimental to muscle function. However, this appears likely only when lactate levels are very high. Elevated lactate levels are only one of many changes that occur within and around muscle cells during intense exercise that can lead to fatigue. Fatigue, which is muscle failure, is a complex subject that depends on more than just changes to lactate concentration. Energy availability, oxygen delivery, perception to pain, and other psychological factors all contribute to muscular fatigue. Elevated muscle and blood lactate concentrations are a natural consequence of any physical exertion. The effectiveness of anaerobic activity can be improved through training.
In 2011, Rubinstein and colleagues used neuroimaging to show decreased brain response to a natural reinforcer (pleasurable food cues) in adolescent light smokers (1–5 cigarettes per day), with their results highlighting the possibility of neural alterations consistent with nicotine dependence and altered brain response to reward even in adolescent low-level smokers.
== Medical Applications/Pharmacology == Hyperglycemia, a side effect caused by diabetes, combines with oxidative stress to create advanced glycation end-products (AGEs) that can lead to diabetic retinopathy (DR), age related macular degeneration (AMD) and cataracts. Enhancing the glyoxalase system has been shown to delay accumulation of AGEs and associated retinal damage in animals that consume higher glycemic index diets. This was corroborated upon over-expression of GLO1, which in C. elegans reduced basal MG concentration, prevented mitochondrial protein modification and enhanced lifespan. Similarly, in mice, GLO1 over-expression reduced baseline MG concentrations in the brain. In diabetic mice, it prevented diabetes-induced increases in MG modification of glomerular proteins, reduced oxidative stress, and prevented development of diabetic kidney pathology, despite unchanged levels of hyperglycemia. Western diets, typically high in glycemic index, exacerbate AGE accumulation and amplify aging-related damage. Enhancing the glyoxalase system may offer a promising therapeutic strategy to prevent the onset and progression of AGEs-related diseases. Oxidative stress can lead to worsening neurological diseases such as Alzheimer's, Parkinson's, and Autism Spectrum Disorder. Flavonoids, a type of antioxidant that combats oxidative stress in the body, has been found to help decrease the production of radical oxygen species (ROS) mostly by preventing the formation of free radicals, additionally they partially enhance the transcription of glyoxalase.
=== Trials for obesity === In March 2021, in a phase III randomized, double-blind trial, 1,961 adults with a body mass index of 30 or greater were assigned in a 2:1 ratio to a treatment with once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention. The trials occurred at 129 sites in 16 countries in Asia, Europe, North America, and South America. The mean percentage change in body weight at week 68 was −14.9% in the semaglutide group vs −2.4% with placebo, for an estimated treatment difference of −12.4 percentage points (95% CI, −13.4 to −11.5). A 2022 review of anti-obesity treatments found that semaglutide as well as tirzepatide (which has an overlapping mechanism of action) were more promising than previous anti-obesity drugs, although less effective than bariatric surgery.
=== Amplification === Most mechanisms of symmetry breaking focus on amplification of an initial stochastic enantiomeric excess. The most likely path for this amplification step is by asymmetric autocatalysis. An autocatalytic chemical reaction is that in which the reaction product is itself a reactive, in other words, a chemical reaction is autocatalytic if the reaction product is itself the catalyst of the reaction. In asymmetric autocatalysis, the catalyst is a chiral molecule, which means that a chiral molecule is catalyzing its own production. An initial enantiomeric excess, such as can be produced by polarized light, then allows the more abundant enantiomer to outcompete the other.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.